News
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
5 Apr 24
News
HUTCHMED And Innovent Announce NDA Acceptance In China For Fruquintinib Combination With Sintilimab For The Treatment Of Advanced Endometrial Cancer With Priority Review Status
2 Apr 24
News
On Wednesday, HUTCHMED Announced Savolitinib sNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
28 Mar 24
News, FDA
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
14 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
13 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
13 Mar 24
Movers
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
13 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
13 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
HUTCHMED Sees FY24 Oncology/Immunology Revenue $300M-$400M
28 Feb 24
News, Guidance
HUTCHMED (China) FY EPS $0.58 Up From $(2.13) YoY, Sales $838.00M Up From $426.41M YoY
28 Feb 24
Earnings, News
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
14 Feb 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
HUTCHMED Presented Phase III Data On Fruquintinib In Second-Line Gastric Cancer At ASCO Plenary Series Session
7 Feb 24
News
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
2 Feb 24
Government, News, Regulations
HUTCHMED Receives ELUNATE Marketing Approval In Hong Kong For Treatment Of Metastatic Colorectal Cancer
30 Jan 24
News
Press releases
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
5 Apr 24
News, Press Releases
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
2 Apr 24
Health Care, Press Releases
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
27 Mar 24
Health Care, Press Releases, General
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
21 Mar 24
Health Care, Press Releases, General
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
28 Feb 24
Earnings, Press Releases
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
6 Feb 24
Health Care, Press Releases
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
2 Feb 24
Press Releases
HUTCHMED to Announce 2023 Final Results
1 Feb 24
News, Press Releases
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
29 Jan 24
Health Care, Press Releases